Astrazeneca PLC (NYSE:AZN) has been given an average rating of “Hold” by the thirty brokerages that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $34.54.

AZN has been the topic of several research analyst reports. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 22nd. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $36.00 to $31.00 in a report on Thursday, July 27th. Argus restated a “buy” rating and set a $35.00 price objective on shares of Astrazeneca PLC in a report on Friday, September 1st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th.

A number of large investors have recently modified their holdings of AZN. Meeder Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter worth about $105,000. WFG Advisors LP boosted its position in Astrazeneca PLC by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in shares of Astrazeneca PLC by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after acquiring an additional 1,769 shares during the period. Quadrant Capital Group LLC boosted its position in shares of Astrazeneca PLC by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock valued at $147,000 after acquiring an additional 846 shares during the period. Finally, Westport Asset Management Inc. bought a new position in shares of Astrazeneca PLC in the second quarter valued at approximately $170,000. Hedge funds and other institutional investors own 14.17% of the company’s stock.

Astrazeneca PLC (NYSE AZN) traded down $0.20 during trading hours on Friday, hitting $32.91. 4,922,389 shares of the stock were exchanged, compared to its average volume of 4,860,991. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.73 and a current ratio of 0.91. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The company has a market cap of $81,530.00, a price-to-earnings ratio of 7.59, a P/E/G ratio of 2.78 and a beta of 0.79.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. Astrazeneca PLC’s revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 earnings per share. equities analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.

WARNING: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/10/astrazeneca-plc-azn-receives-average-rating-of-hold-from-brokerages.html.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.